2025 · FINDING
CITEDREDEFINE 1 (Ph III)
CagriSema achieved 22.7% mean weight loss at 68 weeks; 40.4% of participants lost ≥25%.
⚠ RESEARCH USE ONLY · NOT FDA-APPROVED FOR HUMAN USE · NOT MEDICAL ADVICE
WEIGHT LOSSPHASE 3 TRIALS
Cagrilintide.
The amylin analog making GLP-1s work harder
AKA · AM833 · CagriSema (with semaglutide)
WEIGHT LOSSTRENDINGSUBCUTANEOUS
A long-acting amylin receptor agonist designed to pair with semaglutide. CagriSema showed 22.7% mean weight loss in REDEFINE 1 — approaching retatrutide territory without triple-agonist complexity.
~7 days
Half-life
3
Citations
1
Routes
2
Categories
88
Popularity
AT A GLANCE.
§ 01 · TL;DRTHE QUICK READ.
A long-acting amylin receptor agonist designed to pair with semaglutide. CagriSema showed 22.7% mean weight loss in REDEFINE 1 — approaching retatrutide territory without triple-agonist complexity.
Amylin is the 'second satiety hormone' from your pancreas. Cagrilintide mimics it, slowing gastric emptying and reducing appetite — complementary to GLP-1.
Titrate over 4–16 weeks. Novo Nordisk filing for regulatory approval in 2026.
WHAT IT MIGHT HELP WITH.
1
22.7% weight loss when combined with semaglutide (REDEFINE 1)
2
~8–10% weight loss as monotherapy
3
Fewer GI side effects than maxing GLP-1 alone
4
Weekly injection — matches semaglutide schedule
5
Preserves lean mass better than GLP-1 alone (preliminary data)
HOW IT WORKS.
§ 02 · MECHANISMAmylin is the 'second satiety hormone' from your pancreas. Cagrilintide mimics it, slowing gastric emptying and reducing appetite — complementary to GLP-1.
Long-acting amylin/calcitonin receptor agonist with fatty acid modification for albumin binding. Activates AMY₁–AMY₃ receptors in area postrema and hypothalamus, reducing food intake via a pathway distinct from GLP-1R.
WHO IT'S FOR
- ✓Patients not responding to GLP-1 monotherapy
- ✓Those seeking lean-preserving weight loss
- ✓Research on amylin signaling
WHO SHOULD AVOID
- ✕Personal/family medullary thyroid cancer
- ✕Pregnancy
- ✕Severe GI disease
- ✕Type 1 diabetes
THE RESEARCH.
§ 03 · 3 STUDIES2021 · FINDING
CITEDEnebo et al. — cagrilintide monotherapy
Ph 1b: 10.8% weight loss at 2.4mg weekly over 20 weeks as monotherapy.
2021 · FINDING
Lau et al. — dose-finding
Dose-response established safe and effective range up to 4.5mg weekly.
DOSING PROTOCOL.
§ 04 · DOSINGTYPICAL RANGE
Titrate over 4–16 weeks. Novo Nordisk filing for regulatory approval in 2026.
2.4mg weekly (matches CagriSema Phase III arm)
FREQUENCY
Most-cited schedule
Once weekly subcutaneous
ROUTES
Delivery methods
SUBCUTANEOUS
HALF-LIFE
Steady state drives frequency
~7 days
⚠ NOTE
These are reported protocols from research literature and practitioner accounts, not prescriptions. No FDA-approved human dose exists for research compounds. Anyone using Cagrilintide should work with a qualified physician and source from a supplier providing third-party COAs.
FORMS AVAILABLE
- · Lyophilized or solution; combined with sema in CagriSema
⚠ RESEARCH INFORMATION ONLY · NOT MEDICAL ADVICE
COMMON STACKS.
§ 05 · COMBINATIONSSIDE EFFECTS & RISKS.
§ 06 · SAFETY·
Nausea
Common · mild
Lower incidence than semaglutide alone at equivalent weight-loss
·
Vomiting
Occasional · mild
·
Injection site reactions
Common · mild
•
Hypoglycemia risk in combo with insulin
Monitored · moderate
WHERE TO SOURCE
§ 07 · SUPPLIERPEAK LAB
PEPTIDES
PEPTIDES
SUPPLIER OF RECORD · 12 BATCHES PASSED
We tried nine suppliers across 2025 and kept picking PEAK LAB for Cagrilintide: 99.4% HPLC purity, COA on every batch, cold chain intact. Shop through our link and we earn a small commission — affiliate relationship is disclosed.
◆ THE PEPGAINS DISPATCH
GET THE NEXT UPDATE FIRST.
New research on Cagrilintide + a weekly dispatch on everything else moving in the peptide world. One email. Unsubscribe in a click.